Related Experiment Video
Updated: Jun 11, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer
Zhenyu Nie1,2, Bolong Liu1,3, Jinhui Liu1,2
1Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
Abstract:
Resistance to immunotherapy in bladder cancer has greatly limited its clinical application. Through single-cell sequencing, we determined that ACSM6, an oncogene that is highly expressed in bladder cancer, promotes the abilities of proliferation, cloning, migration, and invasion. The key point is that ACSM6 can also lead to a non-inflammatory immune microenvironment by inhibiting the chemotaxis and tumor killing ability of CD8+ T cells. Survival analysis revealed that high ACSM6 expression was associated with shorter overall survival in the immunotherapy cohort. In summary, ACSM6 is expected to become a novel biomarker for predict bladder cancer progression.
Insights
ACSM6, a bladder cancer oncogene, drives tumor growth and invasion. It also suppresses CD8+ T cell activity, creating a non-inflammatory tumor environment and predicting poor immunotherapy response.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Bladder cancer immunotherapy faces challenges due to treatment resistance.
- ACSM6 is identified as an oncogene overexpressed in bladder cancer.
- Understanding ACSM6's role is crucial for improving bladder cancer treatment.
Discussion:
- ACSM6 promotes bladder cancer cell proliferation, cloning, migration, and invasion.
- ACSM6 induces a non-inflammatory tumor microenvironment by impairing CD8+ T cell function.
- High ACSM6 expression correlates with reduced overall survival in patients receiving immunotherapy.
Key Insights:
- ACSM6 is a key driver of bladder cancer progression.
- ACSM6 negatively impacts anti-tumor immunity by affecting CD8+ T cells.
- ACSM6 expression level serves as a predictive marker for immunotherapy outcomes.
Outlook:
- ACSM6 presents a potential therapeutic target for overcoming immunotherapy resistance in bladder cancer.
- Further research into ACSM6 inhibition could enhance treatment efficacy.
- ACSM6 may serve as a novel biomarker for predicting bladder cancer progression and patient prognosis.
Related Concept Videos
01:27Tumor Immunotherapy
02:23Abnormal Proliferation